These FTSE 100 beauties are just too cheap to miss!

Royston Wild reveals two FTSE 100 (INDEXFTSE: UKX) firecrackers trading far, far too cheaply.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m certain that electricity network operator National Grid (LSE: NG) is one of the best stocks out there for those seeking dependable earnings and dividend growth year after year.

Of course the essential nature of electricity demand puts the company in the box seat when it comes to earnings visibility. But this isn’t National Grid’s only trump card — indeed, RIIO price controls in the UK are helping the business to keep a firm lid on its costs.

And National Grid is embarking on an aggressive expansion scheme on both sides of the Atlantic to keep the bottom line booming, with a view to expanding its asset base by between 5% and 7% per year. Speaking of which, the firm received good news from the US this week when Massachusetts lawmakers permitted the first electricity rate hike since 2010.

Expected earnings growth of 1% and 3% in the periods to March 2017 and 2018 respectively results in P/E ratios of 17.3 times and 16.9 times, just above that of the FTSE 100 (INDEXFTSE: UKX) but still delivering decent value given National Grid’s terrific defensive qualities.

And predicted dividends of 44.4p per share for 2017 and 45.6p for next year create jumbo yields of 4% and 4.1%. These figures outstrip the Footsie average of 3.5% by some distance.

Drugs dynamo

The hit-and-miss nature of medicines development was laid bare by industry giant AstraZeneca (LSE: AZN) in Tuesday trading.

The Cambridge-based business announced that its Brilinta circulation booster had failed to display benefits versus an older blood thinner. A a result, the company has now binned its $3.5bn sales target for the drug for 2016, Brilinta head Ludovic Helfgott told Reuters.

But that’s not to say AstraZeneca isn’t making headway elsewhere. Newly-launched labels like cancer treatments Tagrisso and Lynparza are flying off the shelves, and the company has 145 other projects in the pipeline in fast-growing sectors like respiratory and diabetes.

Indeed, I expect the huge sums AstraZeneca has thrown into developing the next generation of sales drivers — along with booming healthcare demand across the globe — to deliver huge rewards well into the future.

The drugs powerhouse isn’t expected to bounce back into the black just yet though, with AstraZeneca expected to extend four successive earnings bumps. But predicted declines of 3% for both 2016 and 2017 indicate that the revenues rot is finally coming to an end.

These City projections result in P/E ratings of 15.8 times and 16.3 times, peeking above the big-cap average of 15 times. I reckon this represents a fantastic level on which to leap onto AstraZeneca’s rapidly-improving sales outlook.

And for pure value investors, I also reckon estimated dividends of 280 US cents per share for this year and next provide welcome tonic from these marginally-heady multiples. These dividend forecasts yield a market-busting 4.3%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »